NCT05801783

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

Status unknown EARLY_PHASE1 Last updated 6 April 2023

What this trial tests

EARLY_PHASE1 trial testing Recombinant oncolytic herpes simplex virus type 1 (R130) in Ovarian Cancer in 10 participants. Status unknown.

Timeline

2 December 2022

Primary endpoint
2 December 2024

2 December 2025

Quick facts

Lead sponsor	Shanghai Yunying Medical Technology
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	2 December 2022
Primary completion	2 December 2024
Estimated completion	2 December 2025
Sites	1 location across China

Drugs / interventions tested

• Recombinant oncolytic herpes simplex virus type 1 (R130) — full drug profile →

Conditions studied

• Ovarian Cancer — all drugs for Ovarian Cancer →
• Peritoneal Carcinomatosis — all drugs for Peritoneal Carcinomatosis →
• Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →

Sponsor

Shanghai Yunying Medical Technology — full company profile →

Who can join

Adults 18 to 75, female only, with Ovarian Cancer or Peritoneal Carcinomatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

10 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I, R130 in patients with relapsed/refractory ovarian cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
   Tavares V, Marques IS, Melo IG, Assis J, et al · · 2024 · cited 85× · PMID 38339123 · DOI 10.3390/ijms25031845
2. Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment.
   Pampeno C, Opp S, Hurtado A, Meruelo D. · · 2024 · cited 8× · PMID 38474178 · DOI 10.3390/ijms25052925
3. Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
   Vázquez-Arreguín K, Rivera-Caraballo KA, Ventarapragada D, Chiocca EA, et al · · 2025 · cited 6× · PMID 40702727 · DOI 10.1016/j.ymthe.2025.07.034
4. Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.
   Borella F, Carosso M, Chiparo MP, Ferraioli D, et al · · 2025 · cited 4× · PMID 40005517 · DOI 10.3390/pathogens14020140
5. Oncolytic viruses: advanced strategies in cancer therapy.
   Xiao D, Zhang H, Liu Y, Li Y, et al · · 2026 · cited 2× · PMID 41639062 · DOI 10.1038/s41392-025-02343-3
6. Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.
   Zheng Y, Pei Y, Dong C, Liang J, et al · · 2025 · cited 2× · PMID 40872965 · DOI 10.3390/vaccines13080880
7. The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy.
   Mirsky PO, Wagner PL, Mandic-Popov M, Donnenberg VS, et al · · 2025 · cited 1× · PMID 41097743 · DOI 10.3390/cancers17193217